Barclays raised the firm’s price target on SpringWorks Therapeutics to $47 from $41 and keeps an Overweight rating on the shares. The analyst is encouraged by positive early launch dynamics for Ogsiveo. The firm sees strong insurance coverage, academic and community uptake, positive reception from patients and physicians, and says 2024 estimates look reasonable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SWTX:
- 3 Best Stocks to Buy Now, 1/18/2024, According to Top Analysts
- JPMorgan ups SpringWorks target, adds to Analyst Focus List
- SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
- SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
